13.02
+2.22(+20.56%)
Currency In USD
| Previous Close | 10.8 |
| Open | 13.3 |
| Day High | 14.07 |
| Day Low | 12.5 |
| 52-Week High | 16 |
| 52-Week Low | 3.39 |
| Volume | 3.05M |
| Average Volume | 241,950 |
| Market Cap | 171.24M |
| PE | 1.99 |
| EPS | 6.54 |
| Moving Average 50 Days | 9.31 |
| Moving Average 200 Days | 7.07 |
| Change | 2.22 |
If you invested $1000 in Avalo Therapeutics, Inc. (AVTX) since IPO date, it would be worth $0.7 as of September 29, 2025 at a share price of $13.02. Whereas If you bought $1000 worth of Avalo Therapeutics, Inc. (AVTX) shares 5 years ago, it would be worth $1.99 as of September 29, 2025 at a share price of $13.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
GlobeNewswire Inc.
Sep 22, 2025 11:00 AM GMT
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appoi
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Direc
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
GlobeNewswire Inc.
Apr 30, 2025 11:00 AM GMT
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive